Uncategorized

Celcuity wins breast cancer nod, securing ‘differentiated foothold’ in market

Published

on

Celcuity’s first approved drug, Revtorpyk, is indicated for the second-line treatment of advanced HER2- breast cancer patients without PIK3CA mutations—a key use distinction that sets it apart from other PIK3/AKT blockers in the space, according to Jefferies.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version